The role of bevacizumab in hearing preservation and tumor volume control in patients with vestibular schwannomas.
Komotar
Ricardo J
RJ
Starke
Robert M
RM
Sisti
Michael B
MB
Connolly
E Sander
ES
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D034381:Hearing Loss / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D009464:Neuroma, Acoustic / Q000150:complications* / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab